

Table 5. SAEs. Results of pairwise comparisons with sunitinib (all risk groups combined)

Intervention	RCT number (name)	Risk of Bias*	SAEs RR [95% CI]	Clinically relevant In favour of
Lenvantinib + Pembrolizumab	NCT02811861a (CLEAR)	High (D2, 4)	1.52 [1.27, 1.83]	sunitinib
Nivolumab + Ipilimumab	NCT02231749 (Checkmate 214)	High (D2)	1.40 [1.23, 1.59]	sunitinib
Pembrolizumab + Axitinib	NCT02853331 (KEYNOTE-426)	Low	1.29 [1.07, 1.55]	sunitinib
Cabozantinib	NCT01835158 (CABOSUN)	High (D2, 5)	0.92 [0.68, 1.26]	-
Pazopanib	NCT00720941 (COMPARZ)	Some concerns (D2)	0.99 [0.87, 1.14]	-
Nintedanib	NCT01024920	High (D2, 4, 5)	0.91 [0.50, 1.66]	-
Temsirolimus	NCT00979966	High (D1, 2, 4, 5)	0.97 [0.48, 1.95]	-
Atezolizumab + Bevacizumab	NCT01984242 (IMmotion151)	Some concerns (D4, 5)	1.73 [1.19, 2.52]	sunitinib
	NCT02420821	High (D2)	1.11 [0.95, 1.31]	-
Atezolizumab	NCT01984242a	Some concerns (D4, 5)	1.28 [0.85, 1.93]	sunitinib
Everolimus	NCT01108445 (ASPEN)	High (D2, 4, 5)	0.79 [0.62, 1.00]	everolimus
	NCT00903175 (RECORD-3)	Some concerns (D5)	1.03 [0.88, 1.20]	-
Lenvantinib + Everolimus	NCT02811861b (CLEAR)	High (D2)	1.39 [1.15, 1.68]	sunitinib
Sorafenib	NCT00732914 (SWITCH)	High (D4, 5)	1.08 [0.87, 1.34]	-

* D1 Bias arising from the randomization process

D2 Bias due to deviations from intended intervention

D3 Bias due to missing outcome data

D4 Bias in measurement of the outcome

D5 Bias in selection of the reported result